{"disease":{"id":"locally-advanced-or-metastatic-urothelial-carcinoma-uc-with-disease-progression-during-or-following-platinum-containing-chemotherapy-or-within-12-months-of-receiving-neoadjuvant-or-adjuvant-platinum-containing-chemotherapy-in-patients-who-are-not-eligible-for-platinum-containing-chemotherapy-and-have-a-pd-l1-combined-positive-score-cps-10-as-determined-by-an-fda-approved-test-in-combination-with-lenvatinib.md","name":"locally advanced or metastatic urothelial carcinoma uc with disease progression during or following platinum containing chemotherapy or within 12 months of receiving neoadjuvant or adjuvant platinum containing chemotherapy in patients who are not eligible for platinum containing chemotherapy and have a pd l1 combined positive score cps 10 as determined by an fda approved test in combination with lenvatinib.md"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}